Nrf2 pathway (fumaric acid ester)

Assets acting on this target.

Class
Fumaric acid ester

The Nrf2 pathway centers on nuclear factor erythroid 2–related factor 2, a transcription factor that governs the cell's antioxidant and detoxification response. Under normal conditions, Nrf2 is held inactive in the cytoplasm by a partner protein that targets it for degradation. When cells encounter oxidative or electrophilic stress, this restraint is released, allowing Nrf2 to move into the nucleus and switch on genes that produce protective antioxidant enzymes. Fumaric acid esters, such as dimethyl fumarate and its related prodrugs, are small molecules that chemically modify the restraining partner protein, mimicking this stress signal and activating Nrf2 even without genuine oxidative damage. This shifts cells toward a more protective, anti-inflammatory state and also dampens activity of immune signaling pathways involved in inflammation. Because oxidative stress and excessive immune activation both contribute to tissue damage in conditions such as multiple sclerosis and certain inflammatory skin diseases, activating this pathway has broad therapeutic rationale: it can reduce inflammatory cell activity while also supporting cellular resilience against oxidative injury. This dual action (immune modulation combined with cytoprotection) distinguishes fumarate-based therapies from agents that only suppress immune cells without addressing the oxidative component of tissue injury.

By indication

Related mechanisms

Nrf2 pathway (fumaric acid ester) drugs compared

4 drugs, stage by indication
4 drugs acting on Nrf2 pathway (fumaric acid ester): developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
BafiertamCycle Pharmaceuticals Ltd.small molecule (fumarate)ApprovedApproved in Multiple Sclerosis
Dimethyl fumarate (Tecfidera)TecfideraBiogensmall moleculeApprovedApproved in Multiple Sclerosis
Diroximel fumarateVumerityAlkermes plc, Biogensmall molecule (fumarate prodrug)ApprovedApproved in Multiple Sclerosis
Dimethyl fumarate (Skilarence)SkilarenceAlmirallsmall moleculePhase 3Phase 3 in Psoriasis

← all mechanisms